All articles tagged with #glp 1
GLP-1 weight-loss medications may trigger changes in relationship dynamics after substantial weight loss, including increased autonomy and social activity that can strain partnerships; experts warn of a possible rise in separations or divorce as couples adjust, with reports of shifts in libido and intimacy. Some suggest couples therapy or undertaking the weight-loss journey together to mitigate the impact.
Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.
Researchers found that the hormone FGF21 acts in the hindbrain (nucleus of the solitary tract and area postrema) to regulate metabolism and reduce body weight, signaling a shared yet distinct pathway from GLP-1 drugs. The work, published in Cell Reports, suggests a specific brain circuit could be targeted for obesity and MASH therapies, though current FGF21 analogs can cause GI issues and bone loss, prompting hopes for safer, more precise treatments.
A large 23andMe GWAS of 27,885 GLP-1 med users links variants in GLP1R and GIPR to both weight-loss efficacy and nausea risk. A GLP1R missense variant (rs10305420) is associated with about 0.76 kg more weight loss per allele, while GIPR variants predict nausea specifically for tirzepatide (Zepbound/Mounjaro) but not semaglutide. 23andMe’s Total Health service now offers an interactive tool to estimate individual weight loss (roughly 6–20% of starting weight) and side-effect risk, moving toward precision obesity care where genetics is one piece of the puzzle though not the sole determinant.
GLP-1 weight‑loss medications help many people but not everyone; about 10–15% of users in trials didn’t lose at least 5% of their body weight. A Nature study suggests DNA differences may explain this variability, indicating genetics could influence who responds to GLP‑1 therapies.
Amazon Pharmacy will offer Eli Lilly’s new oral GLP-1 drug Foundayo with real-time availability and transparent pricing (insurance as low as $1/day or $25/mo; cash $5/day or $149/mo; automatic coupons), plus Same-Day Delivery nationwide and pharmacist-supported in-office kiosks at select One Medical locations, expanding access from about 3,000 to 4,500 cities by year-end; remote areas will have next-day to three-day delivery.
Nature reports a study of nearly 28,000 23andMe users who used obesity drugs, linking a GLP-1 receptor gene variant to greater weight loss (about 0.76 kg per copy, ~1.5 kg for two copies) over a median of 8 months, and other variants to higher risk of side effects like nausea. Overall genetic effects on weight loss are modest, but associations with adverse effects are stronger; findings come from self-reported data and are not yet ready to guide clinical practice.
Novo Nordisk launched a multi-month Wegovy subscription for its injectable doses and the high-dose pill, offering 3-, 6-, and 12-month plans with fixed monthly prices and potential savings up to $1,200/year for the injection and $600/year for the pill, via telehealth partners; the program aims to improve adherence and pre-empt competition from Eli Lilly’s upcoming oral GLP-1, and patients can opt out anytime (not yet on NovoCare DTC).
A retrospective study of 120 postmenopausal women found that adding menopausal hormone therapy to tirzepatide led to about 19.2% total body weight loss over roughly 18 months, versus 14% with tirzepatide alone, a statistically significant difference. The study is not randomized and did not distinguish hormone therapy types; researchers say controlled trials are needed to confirm the potential synergy and to explore cardiometabolic effects, building on prior work suggesting similar benefits with other GLP-1 drugs plus hormone therapy.
GLP-1 weight-loss injections can jump-start shedding pounds, but long-term success hinges on lifestyle: regular exercise, better food choices, adequate sleep, and attention to mental health. One patient lost 110 pounds after adding a six-days-a-week workout plan. Doctors warn about potential complications (pancreatitis, gallstones, kidney injury) if dosage is increased too quickly or misused, underscoring the need for medical supervision. Access and cost remain barriers, with limited insurance coverage for obesity and forthcoming Medicare coverage; online suppliers may lack dosing guidance and safety information.
U.S. drugmaker Eli Lilly is poised to sign a roughly $2 billion deal with Hong Kong-listed Insilico Medicine to use AI in drug discovery, securing exclusive rights to sell Insilico’s GLP-1 diabetes drug with an upfront $115 million and potential milestone payments that could lift the total beyond $2 billion, underscoring Lilly’s China-focused expansion and its heavy AI investment in pharma.
A 52-week phase-3 trial in 1,698 adults with type 2 diabetes across six countries found orforglipron, a daily oral small-molecule GLP-1 drug, reduced HbA1c more and produced greater weight loss than oral semaglutide (1.71–1.91% vs 1.47% HbA1c and 6.1–8.2 kg vs 5.3 kg), but caused more gastrointestinal side effects and higher discontinuation (~10% vs 4–5%). It’s cheaper to manufacture and doesn’t require refrigeration, giving it logistical advantages, though long-term comparisons with injectable GLP-1 therapies and obesity trials without diabetes are still underway.
A Danish study followed 193 adults after an eight-week very-low-calorie diet and randomized them to exercise, a GLP-1 drug (liraglutide), both, or neither for a year. While the drug helped maintain weight loss, fitness improvements came from exercise—taking the drug without exercising offered little benefit, and combining both yielded the best weight maintenance. Across measures like stair-climb time and VO2 max, exercise consistently boosted fitness, underscoring that GLP-1 meds aren’t a substitute for physical activity.
Jen, 41, who shed 180 pounds on GLP-1, underwent an awake arm lift (brachioplasty) to remove excess skin—about four to five hours under local anesthesia with laughing gas—performed by Dr. Zachary Willis. She shared the journey on TikTok, says the experience wasn’t scary, and hopes to normalize weight-loss–related surgeries as awake options grow with GLP-1 use, with plans for a future awake breast lift.
Denise Richards, 55, publicly shared six angles of her June 2025 facelift, signaling a broader trend: facelifts are increasingly discussed openly as younger patients seek natural-looking rejuvenation. Surgeons report rising demand—partly fueled by social media and advances that enable undetectable results—and note GLP-1 weight‑loss drugs may contribute to sagging skin that prompts lifts. The typical US facelift costs around $11,395 and lasts about 10–15 years. Experts caution buyers to choose board-certified surgeons and avoid marketing hype.